兴科蓉医药2023 中期报告

2023INTERIM REPORT中期報告 Contents 2Corporate Information4Financial Highlights6Corporate Profile7Management Discussion and Analysis23Other Information32Independent Review Report34Interim Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income35Interim Condensed Consolidated Statement of Financial Position37Interim Condensed Consolidated Statement of Changes in Equity38Interim Condensed Consolidated Statement of Cash Flows40Notes to Interim Condensed Financial Information70Definitions Corporate Information 20233 29 BOARD OF DIRECTORSExecutive Directors Mr. Huang Xiangbin(Chairman)Mr. Lei Shifeng (appointed with effect from 29 March 2023) Independent Non-executive Directors Mr. Lau Ying KitMr. Liu WenfangMr. Wang QingMr. Bai Zhizhong AUDIT COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Liu WenfangMr. Wang QingMr. Bai Zhizhong REMUNERATION COMMITTEE 20233 29 Mr. Wang Qing(Chairman)Mr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng (appointed with effect from 29 March 2023) NOMINATION COMMITTEE Mr. Huang Xiangbin(Chairman)Mr. Liu WenfangMr. Lau Ying Kit INTERNAL CONTROL AND CORPORATEGOVERNANCE COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Wang QingMr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng (appointed with effect from 29 March 2023) 20233 29 AUTHORISED REPRESENTATIVES Mr. Huang XiangbinMr. Li Kin Wai JOINT COMPANY SECRETARIESMs. Peng YunluMr. Li Kin Wai REGISTERED OFFICE PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands 2Sinco Pharmaceuticals Holdings LimitedInterim Report 2023 Corporate Information (Continued) CORPORATE HEADQUARTERS E5-1805, Global CentreNo. 1700, North Section of Tianfu AvenueHigh-Tech Zone, ChengduSichuanPRC 1700E5-1805 PRINCIPAL PLACE OF BUSINESS IN HONG KONG Room 2403, Wing On Centre111 Connaught Road CentralHong Kong 1112403 CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 18317M Computershare Hong Kong Investor Services Limited17M Floor, Hopewell Centre,183 Queen’s Road EastWan ChaiHong Kong HONG KONG LEGAL ADVISERTian Yuan Law Firm LLP AUDITOR CL Partners CPA LimitedCertified Public AccountantsRegistered Public Interest Entity Auditor STOCK CODE ON THE MAIN BOARD OF THE STOCKEXCHANGE OF HONG KONG LIMITED 6833 COMPANY’S WEBSITEwww.sinco-pharm.com www.sinco-pharm.com LISTING DATE10 March 2016 20163 10 Financial Highlights •Revenue of the Group slightly decreased by 3.5% or RMB39.8million to RMB1,090.1 million for the Reporting Period (six monthsended 30 June 2022: RMB1,129.9 million), among which revenuefrom sales of pharmaceutical products decreased by approximatelyRMB51.3 million, revenue from medical beauty services increased byRMB11.5 million. •3.5%39.81,090.120226301,129.951.311.5 •39.7152.520226 30192.217.0%14.0% •In line with the decrease in the Group’s revenue, the gross profit ofthe Group decreased by RMB39.7 million to RMB152.5 million forthe Reporting Period (six months ended 30 June 2022: RMB192.2million), while the gross profit margin decreased from 17.0% to14.0%, which was further caused by the increase in the purchasecost due to the fluctuation of the exchange rate. •During the Reporting Period, the net profit decreased byapproximately RMB42.3 million to RMB19.6 million (six monthsended 30 June 2022: RMB61.9 million). Such decrease was mainlydue to the decrease of the Group’s gross profit as stated above. •42.319.620226 3061.9 •19.62022661.942.3 •During the Reporting Period, net profit attributable to owners of theCompany amounted to RMB19.6 million (six months ended June2022: RMB61.9 million), representing a decrease in net profit byRMB42.3 million. •0.0096520226 300.03049 •Basic earnings per share amounted to RMB0.00965 for theReporting Period (six months ended 30 June 2022: RMB0.03049). •Diluted earnings per share amounted to RMB0.00965 for theReporting Period (six months ended 30 June 2022: RMB0.03048). •0.0096520226 300.03048 •The Board resolved not to declare any interim dividend for theReporting Period (six months ended 30 June 2022: Nil). •20226 30 Corporate Profile As a leading MPCM service provider with extensive experience in thedistribution of pharmaceutical imports, the Group focuses on bloodproducts and, based on nationwide marketing and promotion network,provides comprehensive MPCM services for small and medium-sizedoverseas pharmaceuticals manufacturers. The Group’s products areimported from well-known overseas pharmaceuticals manufacturerswith product portfolio centers on blood products as well as anti-infectivemedicine and other prescription medicine. The marketing and promotion services provided by the Groupinclude: coordinating and cooperating w